Abstract
Introduction: To understand the significance of ANLN (anillin, actin-binding protein)-mediated c-Jun N-terminal kinase (JNK) signal pathway on the progression of bladder urothelial carcinoma (BLCA). Methods: The Cancer Genome Atlas (TCGA) database was utilized to perform the clinical significance of ANLN in BLCA. Then, ANLN expression was determined in human normal primary bladder epithelial cells (BdEC) and BLCA cells. Later, ANLN knockdown was performed in BLCA cells, where the expression of MAPK8, MAPK9, and p-JNK/JNK was detected. BLCA cells were divided into the Mock, siNC, siANLN, SP600125 (a selective JNK inhibitor), and ANLN + SP600125 group, followed by measurements of real-time quantitative polymerase chain reaction, 3-4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Annexin V-FITC/PI, Wound-healing, Transwell, and immunofluorescence assays. Results: ANLN was upregulated in the BLCA tissues, which showed a relation with the stage of patients. Besides, BLCA patients with high expression of ANLN had a worse prognosis than those with low expression of ANLN. Besides, the expression of ANLN in the BLCA tissues was positively correlated with MAPK8 and MAPK9. SP600125 suppressed the JNK signal pathway, reduced the proliferation, and increased BLCA cell apoptosis, with the reductions in the invasion and migration and the upregulation of phospho-histone H3 Ser-10 (pHH3), which was abolished by the overexpression of ANLN. Conclusion: ANLN, as an oncogene of BLCA, may associate with the activation of JNK signal pathway. Inhibiting ANLN could deactivate the JNK signal pathway, thereby suppressing the proliferation, invasion, and migration while promoting the apoptosis of BLCA cells.
References
1.
Abdel-Rahman
O
. Squamous cell carcinoma of the bladder: a SEER database analysis
. Clin Genitourin Cancer
. 2017 Jun
;15
(3
):e463
–68
.2.
Necchi
A
, Madison
R
, Raggi
D
, Jacob
JM
, Bratslavsky
G
, Shapiro
O
, . Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder
. Eur Urol
. 2020 Apr
;77
(4
):548
–56
.3.
Heath
EI
, Rosenberg
JE
. The biology and rationale of targeting nectin-4 in urothelial carcinoma
. Nat Rev Urol
. 2021 Feb
;18
(2
):93
–103
.4.
Sun
Z
, Jing
C
, Xiao
C
, Li
T
. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients
. Aging
. 2020 Aug 29
;12
(15
):15624
–37
.5.
Wu
S
, Nitschke
K
, Heinkele
J
, Weis
CA
, Worst
TS
, Eckstein
M
, . ANLN and TLE2 in muscle invasive bladder cancer: a functional and clinical evaluation based on in silico and in vitro data
. Cancers
. 2019 Nov 21
;11
(12
.6.
7.
Tuan
NM
, Lee
CH
. Role of anillin in tumour: from a prognostic biomarker to a novel target
. Cancers
. 2020 Jun 17
;12
(6
):1600
.8.
Naydenov
NG
, Koblinski
JE
, Ivanov
AI
. Anillin is an emerging regulator of tumorigenesis, acting as a cortical cytoskeletal scaffold and a nuclear modulator of cancer cell differentiation
. Cell Mol Life Sci
. 2021 Jan
;78
(2
):621
–33
.9.
Johnson
GL
, Lapadat
R
. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases
. Science
. 2002 Dec 6
;298
(5600
):1911
–2
.10.
Cuschieri
J
, Maier
RV
. Mitogen-activated protein kinase (MAPK)
. Crit Care Med
. 2005 Dec
;33
(Suppl 12
):S417
–9
.11.
Haagenson
KK
, Wu
GS
. Mitogen activated protein kinase phosphatases and cancer
. Cancer Biol Ther
. 2010 Mar 1
;9
(5
):337
–40
.12.
Oleinik
NV
, Krupenko
NI
, Krupenko
SA
. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway
. Oncogene
. 2007 Nov 8
;26
(51
):7222
–30
.13.
Hammouda
MB
, Ford
AE
, Liu
Y
, Zhang
JY
. The JNK signaling pathway in inflammatory skin disorders and cancer
. Cells
. 2020 Apr 2
;9
(4
):857
.14.
Bode
AM
, Dong
Z
. The functional contrariety of JNK
. Mol Carcinog
. 2007 Aug
;46
(8
):591
–8
.15.
Wang
D
, Chadha
GK
, Feygin
A
, Ivanov
AI
. F-actin binding protein, anillin, regulates integrity of intercellular junctions in human epithelial cells
. Cell Mol Life Sci
. 2015 Aug
;72
(16
):3185
–200
.16.
Pljesa-Ercegovac
M
, Savic-Radojevic
A
, Kravic-Stevovic
T
, Bumbasirevic
V
, Mimic-Oka
J
, Simic
T
. Co-localization of GSTP1 and JNK in transitional cell carcinoma of urinary bladder
. Genet Mol Biol
. 2010 Jul
;33
(3
):460
–2
.17.
Ho
IL
, Kuo
KL
, Liu
SH
, Chang
HC
, Hsieh
JT
, Wu
JT
, . MLN4924 synergistically enhances cisplatin-induced cytotoxicity via JNK and Bcl-xL pathways in human urothelial carcinoma
. Sci Rep
. 2015 Nov 23
;5
:16948
.18.
Shen
KH
, Li
CF
, Chien
LH
, Huang
CH
, Su
CC
, Liao
AC
, . Role of galectin-1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway
. Cancer Sci
. 2016 Oct
;107
(10
):1390
–8
.19.
Yu
H
, Wu
CL
, Wang
X
, Ban
Q
, Quan
C
, Liu
M
, . SP600125 enhances C-2-induced cell death by the switch from autophagy to apoptosis in bladder cancer cells
. J Exp Clin Cancer Res
. 2019 Nov 4
;38
(1
):448
.20.
Sugawara
S
, Yamada
Y
, Arai
T
, Okato
A
, Idichi
T
, Kato
M
, . Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis
. J Hum Genet
. 2018 May
;63
(5
):657
–68
.21.
Wang
Y
, Chen
L
, Ju
L
, Qian
K
, Liu
X
, Wang
X
, . Novel biomarkers associated with progression and prognosis of bladder cancer identified by co-expression analysis
. Front Oncol
. 2019
;9
:1030
.22.
Zhang
S
, Nguyen
LH
, Zhou
K
, Tu
HC
, Sehgal
A
, Nassour
I
, . Knockdown of anillin actin binding protein blocks cytokinesis in hepatocytes and reduces liver tumor development in mice without affecting regeneration
. Gastroenterology
. 2018 Apr
;154
(5
):1421
–34
.23.
Takayama
KI
, Suzuki
Y
, Yamamoto
S
, Obinata
D
, Takahashi
S
, Inoue
S
. Integrative genomic analysis of OCT1 reveals coordinated regulation of androgen receptor in advanced prostate cancer
. Endocrinology
. 2019 Feb 1
;160
(2
):463
–72
.24.
Magnusson
K
, Gremel
G
, Ryden
L
, Ponten
V
, Uhlen
M
, Dimberg
A
, . ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer
. BMC Cancer
. 2016 Nov 18
;16
(1
):904
.25.
Wang
D
, Naydenov
NG
, Dozmorov
MG
, Koblinski
JE
, Ivanov
AI
. Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation
. Breast Cancer Res
. 2020 Jan 7
;22
(1
):3
.26.
Maryam
A
, Chin
YR
. ANLN enhances triple-negative breast cancer stemness through TWIST1 and BMP2 and promotes its spheroid growth
. Front Mol Biosci
. 2021
;8
:700973
.27.
Suzuki
C
, Daigo
Y
, Ishikawa
N
, Kato
T
, Hayama
S
, Ito
T
, . ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway
. Cancer Res
. 2005 Dec 15
;65
(24
):11314
–25
.28.
Idichi
T
, Seki
N
, Kurahara
H
, Yonemori
K
, Osako
Y
, Arai
T
, . Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma
. Oncotarget
. 2017 Aug 8
;8
(32
):53180
–93
.29.
Kim
H
, Johnson
JM
, Lera
RF
, Brahma
S
, Burkard
ME
. Anillin phosphorylation controls timely membrane association and successful cytokinesis
. PLoS Genet
. 2017 Jan
;13
(1
):e1006511
.30.
Chuang
C
, Lin
SH
, Huang
F
, Pan
J
, Josic
D
, Yu-Lee
LY
. Acetylation of RNA processing proteins and cell cycle proteins in mitosis
. J Proteome Res
. 2010 Sep 3
;9
(9
):4554
–64
.31.
Chen
AS
, Wardwell-Ozgo
J
, Shah
NN
, Wright
D
, Appin
CL
, Vigneswaran
K
, . Drak/STK17A drives neoplastic glial proliferation through modulation of MRLC signaling
. Cancer Res
. 2019 Mar 15
;79
(6
):1085
–97
.32.
Long
X
, Zhou
W
, Wang
Y
, Liu
S
. Prognostic significance of ANLN in lung adenocarcinoma
. Oncol Lett
. 2018 Aug
;16
(2
):1835
–40
.33.
Inoue
T
, Nakazato
Y
, Karube
Y
, Maeda
S
, Kobayashi
S
, Chida
M
. Mitosis count and number of cancer cells in cases of primary pulmonary adenocarcinoma: correlations among phosphorylated histone 3, number of cancer cells, nuclear grade, pathologic features and prognosis
. Pathol Int
. 2018 Mar
;68
(3
):159
–66
.34.
Elmaci
İ
, Altinoz
MA
, Sari
R
, Bolukbasi
FH
. Phosphorylated histone H3 (PHH3) as a novel cell proliferation marker and prognosticator for meningeal tumors: a short review
. Appl Immunohistochem Mol Morphol
. 2018 Oct
;26
(9
):627
–31
.35.
Ogata
T
, Teshima
T
, Inaoka
M
, Minami
K
, Tsuchiya
T
, Isono
M
, . Carbon ion irradiation suppresses metastatic potential of human non-small cell lung cancer A549 cells through the phosphatidylinositol-3-kinase/Akt signaling pathway
. J Radiat Res
. 2011
;52
(3
):374
–9
.36.
Guo
E
, Mao
X
, Wang
X
, Guo
L
, An
C
, Zhang
C
, . Alternatively spliced ANLN isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma
. Cell Death Dis
. 2021 Aug 3
;12
(8
):764
.37.
Wang
B
, Zhang
XL
, Li
CX
, Liu
NN
, Hu
M
, Gong
ZC
. ANLN promotes carcinogenesis in oral cancer by regulating the PI3K/mTOR signaling pathway
. Head Face Med
. 2021 Jun 3
;17
(1
):18
.38.
Tu
H
, Wu
M
, Huang
W
, Wang
L
. Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis
. Transl Lung Cancer Res
. 2019 Dec
;8
(6
):797
–807
.39.
Pandi
NS
, Manimuthu
M
, Harunipriya
P
, Murugesan
M
, Asha
GV
, Rajendran
S
. In silico analysis of expression pattern of a Wnt/β-catenin responsive gene ANLN in gastric cancer
. Gene
. 2014 Jul 15
;545
(1
):23
–9
.40.
Wu
Q
, Wu
W
, Fu
B
, Shi
L
, Wang
X
, Kuca
K
. JNK signaling in cancer cell survival
. Med Res Rev
. 2019 Nov
;39
(6
):2082
–104
.41.
Bennett
BL
, Sasaki
DT
, Murray
BW
, O’Leary
EC
, Sakata
ST
, Xu
W
, . SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
. Proc Natl Acad Sci U S A
. 2001 Nov 20
;98
(24
):13681
–6
.42.
Liang
T
, Wang
Y
, Wang
Y
, Wang
Y
. Long noncoding RNA PEG10 facilitates bladder cancer cells proliferation, migration, and invasion via repressing microRNA-29b
. J Cell Physiol
. 2019 Nov
;234
(11
):19740
–9
.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
